OTIC

NASDAQ:OTIC

Otonomy, Inc.

  • Stock

0.01

−92.64%

−0.11

USD last updated 13/08 01:59:42

Last Close

0.12

11/04 19:58

Market Cap

582.48K

Beta: 1.57

Volume Today

1.94M

Avg: 876.96K

PE Ratio

−0.01

PFCF: −0.02

Dividend Yield

1,294.12%

Payout:0%

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase II...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -1.2-1-0.8-0.6-0.4-0.22013-09-302016-03-072018-03-082020-02-272022-02-28

    Revenue (Estimate*)

    100K200K300K400K2013-09-302016-03-072018-03-082020-02-272022-02-28

    *Estimate based on analyst consensus